Dataset Information

Gene expression profile correlates with overall survival in patients with resected pancreatic adenocarinoma

ABSTRACT: Purpose/Objective(s): To correlate gene expression and overall survival (OS) in patients with pancreatic adenocarcinoma who have undergone definitive surgery Materials/Methods: Patients were identified that were treated with definitive surgery without neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma. The Beaumont BioBank consented patients then collected and stored tissue samples. Patients were grouped into short term (<10 months, n=13) and long term (>20 months, n=11) survivors. RNA was extracted from fresh frozen tissues, and global gene expression patterns in the short and longer-term survivors were compared. Pathway analysis of the significant genes was also performed. Results: The median age at the time of surgery was 64 years. The mean overall survival in each group was 7.5 months and 32.0 months. We identified 163 genes that were differentially expressed between patients who survived <10 months and >20 months from their definitive surgery. Many of the genes identified have known prognostic importance in oncology; however, less than half of these genes have been reported to be associated with survival in pancreatic adenocarcinoma. Pathway analysis identified expression targets of SP1, JUN, and EGF to be highly regulated based upon differences in overall survival. Conclusions: In pancreatic adenocarcinoma patients who have undergone definitive resection, we have identified multiple genes associated with inferior survival. Many of the genes reported in this study have not previously been linked to overall survival in this patient population.

ORGANISM(S): Homo sapiens

PROVIDER: GSE77435 | GEO | 2017/12/01

SECONDARY ACCESSION(S): PRJNA310327

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma Pancreatic ductal adenocarcinoma (PDAC), comprising over 90% of all pancreatic cancers, remains a lethal disease with an estimated 232,000 new cases, 227,000 deaths per year worldwide, and a less than 5% five-year survival rate. Currently the standard of care for the 20% of patients with localized disease is surgery followed by chemotherapy, and in some cases radiation. Unfortunately despite the use of adjuvant therapy, median survival remains at best 23 months. It is important to note however, that up to 27% of patients with resected PDAC can survive for five years. However, in these studies examining actual long-term survivors, only two have found that adjuvant therapy was associated with improved survival. In addition, randomized controlled trials of gemcitabine-based chemotherapy demonstrate an improvement in median survival of at best 3 months. One possible conclusion from these studies is that tumor biology dictates outcome and that our current adjuvant therapy has only a modest impact on altering a patient's course.Hypothesizing that the dismal outcome of patients with localized disease is due to the presence of micrometastasic disease, current clinical investigation has focused on preoperative or neoadjuvant therapy. This approach, where patients who cannot tolerate the stress of therapy or develop metastatic disease during treatment are spared surgery, has demonstrated an overall survival of 34 months in this highly selected patient population. Therefore the ability to select patients who would most benefit from a neoadjuvant approach may be important. One way to do this is to define a prognostic gene signature that can identify patients with more aggressive tumor biology upfront. reference x sample The 30 Nebraska and UNC samples were not analyzed with clinical data so it is not provided. One of the PE samples is missing some clinical data.

Project description:Pancreatic cancer is a highly malignant tumor in the digestive tract, with its incidence increasing year by year. Due to the insidious onset and rapid progression, most patients have already advanced disease at the time of the initial diagnosis, and the overall 5-year survival rate was only 11%. Tumors in T4 stage often have the invasion of key upperabdominal vessels, mainly referring to artery-involved pancreatic cancer with a worse prognosis. Resection of pancreatic ductal adenocarcinoma (PDAC) with T4 stage is more challenging and usually needs advanced surgical techniques including treatment of the involved artery including sub-adventitial divestment technique (SDT) and arterial resection with reconstruction, and periarterial dissection such as the Heidelberg Triangle Operation. SDT means a technique to separate the tumor from the artery by dissecting into the plane between the external elastic lamina (EEL) and the tunic media when the tumor was not invaded to EEL of the involved artery. Our previous study revealed that SDT procedure appears to be relatively safe, without excessive mortality, as compared to arterial resection with reconstruction. However, survival times can vary widely among different patients. So a strategy to select the T4 patients who may benefit from the surgery with SDT procedure is urgently needed. Our previous RNA-seq dataset has identified a series of differentially expressed circRNAs including circNEIL3 and circRHOBTB3 in PDACs. These results suggested that circRNAs might be prominent prognostic markers for PDAC. So to explore the prognostic value of circRNAs in pancreatic cancer and seek a useful biomarker for distinguishing specified population with a good prognosis from the whole T4 patients, we further performed whole transcriptome sequencing including miRNAs, mRNAs, lncRNAs and circRNAs in ten PDAC cancer samples with T4 stage but diametrically opposing survival outcomes. They all underwent radical surgery and received the assessments of pre- and post-operative contrast-enhanced computed tomography, five of these patients developed newly discovered metastasis soon after surgery and died within 4-9 months. In contrast, the other five patients had no recurrence or metastasis and had long-term survival for more than 39 months. We systematically identified differentially expressed circRNAs in our previous dataset and in patients with T4 stage through combining three popular circRNAs detection algorithms (CIRI2 v2.0.6, CIRCexplorer2 v2.3.8, and find_circ v1.2) and two differential analysis methods (DEGseq and DEseq). Results were validated by using quantitative RT-PCR. circRNA alternative splicing events and highly expressed circRNAs with high circular ratio were also identified by CircSplice and CIRCexplorer3-CLEAR pipeline.

Dataset Information

Gene expression profile correlates with overall survival in patients with resected pancreatic adenocarinoma

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets